Wang Y H, Li F, Luo B, Wang X H, Sun H C, Liu S, Cui Y Q, Xu X X
Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, People's Republic of China.
Neoplasma. 2009;56(5):371-8. doi: 10.4149/neo_2009_05_371.
We used flow cytometry and a DNA-binding dye efflux assay to isolate a side population (SP) of cells with stem cell characteristics from the human pancreatic carcinoma cell line, PANC-1. Non-obese diabetic/severe combined immunodeficiency mouse xenograft experiments showed that SP cells were enriched in tumor initiating capability compared with non-SP cells. Cultured SP cells were able to differentiate into daughter cells and non-SP cells, through asymmetric division. Our study demonstrated that SP cells had high drug-resistance, both in vivo and in vitro. SP cells also showed significantly higher levels of mRNA expression for CD133, ABCG2 and Notch1, when compared to non-SP cells. Furthermore, xenografted tumors derived from injected SP cells and treated with gemcitabine had more CD133+ cells than untreated ones. We therefore suggest that these SP cells from the PANC-1 cell line were enriched with cancer stem cells.
我们使用流式细胞术和DNA结合染料外排试验，从人胰腺癌细胞系PANC-1中分离出具有干细胞特征的细胞侧群（SP）。非肥胖糖尿病/严重联合免疫缺陷小鼠异种移植实验表明，与非SP细胞相比，SP细胞的肿瘤起始能力更强。培养的SP细胞能够通过不对称分裂分化为子代细胞和非SP细胞。我们的研究表明，SP细胞在体内和体外均具有高耐药性。与非SP细胞相比，SP细胞中CD133、ABCG2和Notch1的mRNA表达水平也显著更高。此外，注射SP细胞并接受吉西他滨治疗的异种移植肿瘤中，CD133+细胞比未治疗的更多。因此，我们认为来自PANC-1细胞系的这些SP细胞富含癌症干细胞。
